Health · Medical Research · 1 hr ago
Blood protein changes linked to memory and brain differences in Down syndrome
Researchers studied a blood protein called β-synuclein in adults with Down syndrome, who can develop Alzheimer’s-related brain changes.
They compared 88 adults with Down syndrome at different stages of Alzheimer’s disease with 43 people without Down syndrome.
β-synuclein levels were higher in participants with Down syndrome, and age-based estimates suggested the difference appeared about 21 years before expected Alzheimer’s symptoms.
Higher levels were also associated with signs of brain change and poorer episodic memory, which involves recalling events.
The findings suggest the protein could help researchers study early changes in brain connections, but they do not show that it causes those changes.
Because the study compared participants at one point in time, further research is needed to establish how the protein changes as the disease progresses.
A study found that serum β-synuclein levels were higher in adults with Down syndrome and increased with age.
The levels diverged from those in controls about 21 years before expected Alzheimer’s disease symptom onset.
Higher β-synuclein was associated with brain hypometabolism, cortical atrophy and poorer episodic memory.
The findings suggest the protein may help researchers track Alzheimer’s-related synaptic changes in people with Down syndrome.
- Who
- Researchers studied adults with Down syndrome and cognitively unimpaired controls without Down syndrome.
- What
- The study examined links between blood β-synuclein levels, memory and brain changes.
- When
- Published on October 12, 2026. The study’s data collection dates are not stated.
- Where
- The study involved participants in the Down Alzheimer Barcelona Neuroimaging Initiative and the Sant Pau Initiative in Neurodegeneration.
- Why
- Researchers examined whether β-synuclein could help track Alzheimer’s-related synaptic changes in people with Down syndrome.
This story does not have two clearly opposing sides.
No direct quotes in the coverage so far.
This story does not have a timeline yet.
- Participants with Down syndrome
- 88 adults: 35 without AD symptoms, 18 with prodromal AD and 35 with AD dementia
- Control group
- 43 cognitively unimpaired people without Down syndrome
- Biomarker divergence
- About 21 years before expected Alzheimer’s disease symptom onset
- Imaging
- MRI scans from 60 participants with Down syndrome; FDG-PET scans from 42
- Publication
- Alzheimer’s & Dementia; October 12, 2026
Sources
Related news
Pope Leo to have surgery to remove an early-detected lung nodule
Worsening vision linked to higher dementia risk in 16-year study
Pope Leo XIV to have surgery to remove early-stage lung nodule
Seven days of strength training changed fat tissue in obese mice
Pope Leo XIV to have lung nodule removed in surgery this week
Cash rewards increased smoking abstinence in trial of underserved patients
South Korea to publish first government tests of tobacco harmful substances
Australian trial finds no clear overall effect from childcare active-play program
Experts urge parents to watch for persistent childhood cancer symptoms
Broken heart syndrome can mimic a heart attack and needs urgent assessment
Brain injuries may contribute to chronic homelessness, Canadian doctor says
